News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
After TKI , adding Pembro to chemo DOES NOT improve OS – Rami Manochakian
Photo: Rami Manochakian/ASCO
Jun 7, 2023, 10:31

After TKI , adding Pembro to chemo DOES NOT improve OS – Rami Manochakian

NEGATIVE results of Keynote789 trial:

Platinum + Pem +/- Pembro for TKI-resistant EGFR mutant NSCLC

❌PFS HR 0.8, P=0.0122
mPFS: 5.6 vs 5.5 mths

❌OS HR 0.84, P=0.0362
mOS: 15.9 vs 14.7 mths

After TKI , adding Pembro to chemo DOES NOT improve OS

Source: Rami Manochakian / Twitter

 

ASCO2023 Keynote789 Pembro Rami Manochakian TKI
Special Coverage
Blog
Nov 1, 2024, 20:27
Amy Oxentenko: Honored to be inducted as President of the American College of Gastroenterology
Blog
Nov 1, 2024, 20:22
Yan Leyfman: Honored to present our research at the 2024 Lymphoma, Leukemia and Myeloma Congress
Blog
Nov 1, 2024, 20:05
The Official Programme for Advancing Paediatric Oncology on Children’s Rights Day is Out - SIOP Europe
Blog
Nov 1, 2024, 19:20
Chandler Park: Dr. Petros Grivas answers the most important question for junior faculty
Blog
Nov 1, 2024, 19:12
ESTRO: Toxicity Profile of Immune Therapy Combined with Radiotherapy
Insight
Nov 1, 2024, 17:59
Ajay Major: Collect long-term follow-up data in survivors of Hodgkin lymphoma with the MyHodgkin MyHealth app
Blog
Nov 1, 2024, 17:52
Habib Nehmé: Strengthening Presence in Saudi Arabia’s Radiotherapy and Oncology Market
Blog
Nov 1, 2024, 17:46
Hidehito Horinouchi: Early Stage NSCLC at ACLC24 session
Blog
Nov 1, 2024, 17:41
Yelak Biru's interview with News 9 about the work IMF does
Insight
Nov 1, 2024, 17:31
Francisco Esteva: ADCs are making waves in the fight against advanced HER2+ breast cancer
Blog
Nov 1, 2024, 17:27
Alcohol consumption increases the risk of cancer at 7 sites - IARC
Blog
Nov 1, 2024, 17:17
Raul Cordoba: Valemetostat for relapsed or refractory peripheral T-cell lymphoma